GU Cancers 2020 | SIP-T: autologous T-cells for prostate cancer

Name: SIP-T: autologous T-cells for prostate cancer
Uploaded: 2020-02-15T15:42:58Z
Description: Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses the association between humoral antigen spread with cytotoxic T lymphocyte activity after sipuleucel-T (SIP-T) treatment in two Phase II clinical studies: STAMP and STRIDE. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Daniel Petrylak • 15 Feb 2020

GU Cancers 2020

Genitourinary Cancer Prostate Cancer Abiraterone Enzalutamide Sipuleucel-T

STAMP STRIDE

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses the association between humoral antigen spread with cytotoxic T lymphocyte activity after sipuleucel-T (SIP-T) treatment in two Phase II clinical studies: STAMP and STRIDE. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.